Skip to main content
SpringerLink
Log in

A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma

An Illinois cancer center study

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Echinomycin, a cyclic peptide in the family of quinoxaline antibiotics, was evaluated in patients with metastatic, soft tissue sarcoma not previously treated for metastatic disease. The starting dose of echinomycin was 1,200 mcg/m2 administered intravenously, once weekly × 4, followed by a two-week break. The protocol design called for dose escalation on subsequent cycles of therapy, but because of significant toxicity, dose escalation occurred in only 5 of 25 treatment cycles. Severe nausea and vomiting was the most common toxicity. No clinical responses were observed in the 12 evaluable patients. Echinomycin at this dose and schedule is inactive in metastatic soft tissue sarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Corbaz R, Ettinger L, Gaumann E, Keller-Schierlein W, Kradolfer S, Neipp L, Prelog V, Reusser P, Zahner H: Metabolic products of actinomycetes. VII. Echinomycin. Helv Chim Acta 40:199–204, 1957

    Google Scholar 

  2. Martin DG, Misak SA, Biles C, Stewart JC, Baczynskyj L, Meulmann PA: Structure of quinomycin antibiotics. J Antibiot 28:332–336, 1975

    Google Scholar 

  3. Ward DC, Reich E, Goldberg IH: Base specificity in the interaction of polynucleotides with antibiotic drugs. Science 149:1259–1263, 1965

    Google Scholar 

  4. Wakelin LPG, Waring MJ: The binding of echinomycin to deoxyribonucleic acid. Biochem J 157:721–740, 1976

    Google Scholar 

  5. Lathan B, Von Hoff DD: Cytotoxin activity of echinomycin in a human tumor cloning system. Cancer Drug Delivery 1:191–198, 1984

    Google Scholar 

  6. Kuhn J, Von Hoff D, Hersh M: Phase I trial of echinomycin (NSC-526417), a bifunctional intercalating agent, administered by 24 hour continuous infusion. Eur J Cancer Clin Oncol 25:797–803, 1989

    Google Scholar 

  7. Pazdur R, Haas CD, Baker LH, Leichman CG, Decker D: Phase I study of echinomycin. Cancer Treat Rep 71:117–119, 1987

    Google Scholar 

  8. Harvey JH, McFadden M, Andrews WG, Byre PJ: Phase I study of echinomycin administered on an intermittent bolus schedule. Cancer Treat Rep 69:1365–1368, 1985

    Google Scholar 

  9. Wingo PA, Tong T, Bolder S: Cancer statistics, 1995. CA Cancer J Clin 5:8–30, 1995

    Google Scholar 

  10. Antman KH: Sarcoma of bone and soft tissue. In: Perry MC (ed). The Chemotherapy Sourcebook. Baltimore, Williams and Wilkins, pp. 1068–1093, 1992

    Google Scholar 

  11. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981

    Google Scholar 

  12. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481, 1958

    Google Scholar 

  13. Shevrin DH, Lad TE, Guinan P, Kilton LJ: Phase II trial of echinomycin in advanced hormone-resistant prostate cancer. An Illinois Cancer Council study. Invest New Drugs 12:65–66, 1994

    Google Scholar 

  14. Wadler S, Terteromano L, Cazenave L, Sparano JA: Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. Cancer Chemother Pharmacol 34:266–269, 1994

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Medical Oncology, Department of Medicine, Northwestern University, Chicago, IL

    William J. Gradishar & Al. B. Benson III

  2. Section of Hematology/Medical Oncology, Department of Medicine, University of Chicago, Chicago, IL

    Nicholas J. Vogelzang

  3. Kilton Hematology/Oncology Practice, Elgin, IL

    Lary J. Kilton

  4. Northwest Oncology, P.C., Elk Grove Village, IL

    Steven J. Leibach

  5. Biometry Section, Robert H. Lurie Cancer Center, Northwestern University, Chicago, IL

    Alfred W. Rademaker

  6. Illinois Cancer Center, Chicago, IL, USA

    Alfred W. Rademaker, Suzanne French & Al. B. Benson III

Authors
  1. William J. Gradishar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicholas J. Vogelzang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lary J. Kilton
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Steven J. Leibach
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alfred W. Rademaker
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Suzanne French
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Al. B. Benson III
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gradishar, W.J., Vogelzang, N.J., Kilton, L.J. et al. A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. Invest New Drugs 13, 171–174 (1995). https://doi.org/10.1007/BF00872868

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00872868

Key words

Search

Navigation